SCHEMBL12699161

SCHEMBL12699161

CC1(C)CCC[C@]1(C)C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
CYP2C19 P33261 1/20 0.38
PKM P14618 1/20 0.36
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
FFAR3 O14843 1/20 0.31
KDM4E B2RXH2 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199589 1.00 TSHR (0.38) TSHRNFKB1CYP2C19PKMTDP1
SCHEMBL16533608 0.95 PKM (0.36) TSHRNFKB1CYP2C19PKMTDP1
SCHEMBL8165588 0.77 TSHR (0.39) TSHRNFKB1CYP2C19FFAR3
SCHEMBL3315131 0.77 FFAR3 (0.43) TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL14396686 0.77 FFAR3 (0.43) TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL8164553 0.77 TSHR (0.39) TSHRNFKB1CYP2C19FFAR3
SCHEMBL8164550 0.77 TSHR (0.39) TSHRNFKB1CYP2C19FFAR3
SCHEMBL14362836 0.77 FFAR3 (0.43) TSHRNFKB1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL28770199 0.74 TSHR (0.35) TSHRNFKB1CYP2C19FFAR3
SCHEMBL27428658 0.73 PKM (0.34) TSHRNFKB1CYP2C19PKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2685981-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2016-08-24 EP disclosed
WO-2012125886-A1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2012-09-20 WO disclosed